Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 24

1.

Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial.

Robert C, Ribas A, Wolchok JD, Hodi FS, Hamid O, Kefford R, Weber JS, Joshua AM, Hwu WJ, Gangadhar TC, Patnaik A, Dronca R, Zarour H, Joseph RW, Boasberg P, Chmielowski B, Mateus C, Postow MA, Gergich K, Elassaiss-Schaap J, Li XN, Iannone R, Ebbinghaus SW, Kang SP, Daud A.

Lancet. 2014 Jul 14. pii: S0140-6736(14)60958-2. doi: 10.1016/S0140-6736(14)60958-2. [Epub ahead of print]

PMID:
25034862
[PubMed - as supplied by publisher]
2.

Vemurafenib: an evidence-based review of its clinical utility in the treatment of metastatic melanoma.

Swaika A, Crozier JA, Joseph RW.

Drug Des Devel Ther. 2014 Jun 16;8:775-87. doi: 10.2147/DDDT.S31143. eCollection 2014.

PMID:
24966667
[PubMed - in process]
Free PMC Article
3.

Inverse association between programmed death ligand 1 and genes in the VEGF pathway in primary clear cell renal cell carcinoma.

Joseph RW, Parasramka M, Eckel-Passow JE, Serie D, Wu K, Jiang L, Kalari K, Thompson RH, Huu Ho T, Castle EP, Cheville J, Kwon ED, Thompson EA, Parker A.

Cancer Immunol Res. 2013 Dec;1(6):378-85. doi: 10.1158/2326-6066.CIR-13-0042. Epub 2013 Aug 29.

PMID:
24778130
[PubMed - in process]
4.

Follicular Dendritic Cell Sarcoma Presenting As a Thyroid Mass.

Starr JS, Attia S, Joseph RW, Menke D, Casler J, Smallridge RC.

J Clin Oncol. 2014 Mar 24. [Epub ahead of print] No abstract available.

PMID:
24663046
[PubMed - as supplied by publisher]
5.

Severe cutaneous and neurologic toxicity in melanoma patients during vemurafenib administration following anti-PD-1 therapy.

Johnson DB, Wallender EK, Cohen DN, Likhari SS, Zwerner JP, Powers JG, Shinn L, Kelley MC, Joseph RW, Sosman JA.

Cancer Immunol Res. 2013 Dec;1(6):373-7. doi: 10.1158/2326-6066.CIR-13-0092.

PMID:
24490176
[PubMed - in process]
6.

ANKS1B is a smoking-related molecular alteration in clear cell renal cell carcinoma.

Eckel-Passow JE, Serie DJ, Bot BM, Joseph RW, Cheville JC, Parker AS.

BMC Urol. 2014 Jan 31;14:14. doi: 10.1186/1471-2490-14-14.

PMID:
24479813
[PubMed - in process]
Free PMC Article
7.

Higher Expression of Topoisomerase II Alpha Is an Independent Marker of Increased Risk of Cancer-specific Death in Patients with Clear Cell Renal Cell Carcinoma.

Parker AS, Eckel-Passow JE, Serie D, Hilton T, Parasramka M, Joseph RW, Wu KJ, Cheville JC, Leibovich BC.

Eur Urol. 2013 Dec 25. pii: S0302-2838(13)01365-1. doi: 10.1016/j.eururo.2013.12.017. [Epub ahead of print]

PMID:
24388441
[PubMed - as supplied by publisher]
8.

Loss of BAP1 protein expression is an independent marker of poor prognosis in patients with low-risk clear cell renal cell carcinoma.

Joseph RW, Kapur P, Serie DJ, Eckel-Passow JE, Parasramka M, Ho T, Cheville JC, Frenkel E, Rakheja D, Brugarolas J, Parker A.

Cancer. 2014 Apr 1;120(7):1059-67. doi: 10.1002/cncr.28521. Epub 2013 Dec 30. Erratum in: Cancer. 2014 Jun 1;120(11):1752-3.

PMID:
24382589
[PubMed - indexed for MEDLINE]
9.

Somatic expression of ENRAGE is associated with obesity status among patients with clear cell renal cell carcinoma.

Eckel-Passow JE, Serie DJ, Bot BM, Joseph RW, Hart SN, Cheville JC, Parker AS.

Carcinogenesis. 2014 Apr;35(4):822-7. doi: 10.1093/carcin/bgt485. Epub 2013 Dec 28.

PMID:
24374825
[PubMed - indexed for MEDLINE]
10.

An integrated model of the transcriptome of HER2-positive breast cancer.

Kalari KR, Necela BM, Tang X, Thompson KJ, Lau M, Eckel-Passow JE, Kachergus JM, Anderson SK, Sun Z, Baheti S, Carr JM, Baker TR, Barman P, Radisky DC, Joseph RW, McLaughlin SA, Chai HS, Camille S, Rossell D, Asmann YW, Thompson EA, Perez EA.

PLoS One. 2013 Nov 1;8(11):e79298. doi: 10.1371/journal.pone.0079298. eCollection 2013.

PMID:
24223926
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma.

Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, Wolchok JD, Hersey P, Joseph RW, Weber JS, Dronca R, Gangadhar TC, Patnaik A, Zarour H, Joshua AM, Gergich K, Elassaiss-Schaap J, Algazi A, Mateus C, Boasberg P, Tumeh PC, Chmielowski B, Ebbinghaus SW, Li XN, Kang SP, Ribas A.

N Engl J Med. 2013 Jul 11;369(2):134-44. doi: 10.1056/NEJMoa1305133. Epub 2013 Jun 2.

PMID:
23724846
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

Age-period-cohort analysis of renal cell carcinoma in United States adults.

Tyson MD, Humphreys MR, Parker AS, Thiel DD, Joseph RW, Andrews PE, Castle EP.

Urology. 2013 Jul;82(1):43-7. doi: 10.1016/j.urology.2013.02.065. Epub 2013 May 22.

PMID:
23706585
[PubMed - indexed for MEDLINE]
13.

Ultrathin primary is a marker for worse prognosis in lymph node-positive cutaneous melanoma.

Bagaria SP, Ray PS, Joseph RW, Heckman MG, Rawal B, Gray RJ, Pockaj B, Wasif N.

Cancer. 2013 May 15;119(10):1860-7. doi: 10.1002/cncr.27985. Epub 2013 Feb 13.

PMID:
23408288
[PubMed - indexed for MEDLINE]
14.

Characterizing the clinical benefit of ipilimumab in patients who progressed on high-dose IL-2.

Joseph RW, Eckel-Passow JE, Sharma R, Liu P, Parker A, Jakob J, Buchbinder E, Bassett RL, Davies MA, Hwu P, Atkins MB, Sullivan RJ.

J Immunother. 2012 Nov-Dec;35(9):711-5. doi: 10.1097/CJI.0b013e3182742c27.

PMID:
23090080
[PubMed - indexed for MEDLINE]
15.

Evaluation of the association of prostate cancer-specific anxiety with sexual function, depression and cancer aggressiveness in men 1 year following surgical treatment for localized prostate cancer.

Tavlarides AM, Ames SC, Diehl NN, Joseph RW, Castle EP, Thiel DD, Broderick GA, Parker AS.

Psychooncology. 2013 Jun;22(6):1328-35. doi: 10.1002/pon.3138. Epub 2012 Aug 1.

PMID:
22855322
[PubMed - indexed for MEDLINE]
16.

Oncogenic BRAF(V600E) promotes stromal cell-mediated immunosuppression via induction of interleukin-1 in melanoma.

Khalili JS, Liu S, Rodríguez-Cruz TG, Whittington M, Wardell S, Liu C, Zhang M, Cooper ZA, Frederick DT, Li Y, Zhang M, Joseph RW, Bernatchez C, Ekmekcioglu S, Grimm E, Radvanyi LG, Davis RE, Davies MA, Wargo JA, Hwu P, Lizée G.

Clin Cancer Res. 2012 Oct 1;18(19):5329-40. doi: 10.1158/1078-0432.CCR-12-1632. Epub 2012 Jul 31.

PMID:
22850568
[PubMed - indexed for MEDLINE]
Free PMC Article
17.

A randomized phase II study of cilengitide (EMD 121974) in patients with metastatic melanoma.

Kim KB, Prieto V, Joseph RW, Diwan AH, Gallick GE, Papadopoulos NE, Bedikian AY, Camacho LH, Hwu P, Ng CS, Wei W, Johnson MM, Wittemer SM, Vardeleon A, Reckeweg A, Colevas AD.

Melanoma Res. 2012 Aug;22(4):294-301. doi: 10.1097/CMR.0b013e32835312e4.

PMID:
22668797
[PubMed - indexed for MEDLINE]
Free PMC Article
18.

Vitamin D receptor upregulation in alloreactive human T cells.

Joseph RW, Bayraktar UD, Kim TK, St John LS, Popat U, Khalili J, Molldrem JJ, Wieder ED, Komanduri KV.

Hum Immunol. 2012 Jul;73(7):693-8. doi: 10.1016/j.humimm.2012.04.019. Epub 2012 Apr 28.

PMID:
22548720
[PubMed - indexed for MEDLINE]
19.

Therapy for metastatic melanoma: the past, present, and future.

Finn L, Markovic SN, Joseph RW.

BMC Med. 2012 Mar 2;10:23. doi: 10.1186/1741-7015-10-23. Review.

PMID:
22385436
[PubMed - indexed for MEDLINE]
Free PMC Article
20.

NRAS mutation status is an independent prognostic factor in metastatic melanoma.

Jakob JA, Bassett RL Jr, Ng CS, Curry JL, Joseph RW, Alvarado GC, Rohlfs ML, Richard J, Gershenwald JE, Kim KB, Lazar AJ, Hwu P, Davies MA.

Cancer. 2012 Aug 15;118(16):4014-23. doi: 10.1002/cncr.26724. Epub 2011 Dec 16.

PMID:
22180178
[PubMed - indexed for MEDLINE]
Free PMC Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk